Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
SMFL Smart for Life	$0.01 +636.4%	$0.01	$0.00 ▼ $1.56	$57K	17.05	6,199 shs	672 shs
TCON TRACON Pharmaceuticals	$0.03	$0.04	$0.00 ▼ $14.75	$110K	1.37	120,908 shs	23,886 shs
TRVN Trevena	$0.25 +20,733.3%	$0.70	$0.00 ▼ $7.85	$240K	0.41	2,161 shs	6,905 shs
WINT Windtree Therapeutics	$0.10 -0.9%	$0.61	$0.09 ▼ $487.50	$348K	0.63	5.76 million shs	233,507 shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
SMFL Smart for Life	+1,000.00%	-89.81%	-52.17%	+175.00%	-99.90%
TCON TRACON Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	-74.11%
TRVN Trevena	-99.56%	-99.56%	-99.87%	-99.90%	-99.97%
WINT Windtree Therapeutics	-6.29%	-28.25%	-87.94%	-87.45%	-99.98%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
SMFL Smart for Life	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TCON TRACON Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TRVN Trevena	1.2465 of 5 stars	3.0	2.0	0.0	0.0	0.0	0.0	0.6
WINT Windtree Therapeutics	2.2744 of 5 stars	3.0	4.0	0.0	0.0	2.0	0.0	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
SMFL Smart for Life	0.00	N/A	N/A	N/A
TCON TRACON Pharmaceuticals	0.00	N/A	N/A	N/A
TRVN Trevena	2.00	Hold	$5.00	1,900.00% Upside
WINT Windtree Therapeutics	2.00	Hold	$350.00	367,933.65% Upside

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
SMFL Smart for Life	$11.11M	0.01	N/A	N/A	($17.10) per share	0.00
TCON TRACON Pharmaceuticals	$12.05M	0.01	$1.61 per share	0.02	($0.37) per share	-0.09
TRVN Trevena	$443K	0.54	N/A	N/A	($11.07) per share	-0.02
WINT Windtree Therapeutics	N/A	N/A	N/A	N/A	$0.98 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
SMFL Smart for Life	-$22.68M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
TCON TRACON Pharmaceuticals	-$3.59M	$3.73	0.01	∞	N/A	N/A	-237.65%	57.29%	N/A
TRVN Trevena	-$40.29M	-$47.04	N/A	N/A	N/A	N/A	N/A	-119.55%	11/5/2025 (Estimated)
WINT Windtree Therapeutics	-$1.79M	-$823.47	N/A	N/A	N/A	N/A	-207.34%	-50.19%	N/A

Latest TCON, WINT, SMFL, and TRVN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/19/2025	Q2 2025	WINT Windtree Therapeutics	-$99.00	-$3.06	+$95.94	-$3.06	$3.00 million	N/A
6/11/2025	Q3 2024	SMFL Smart for Life	N/A	-$0.94	N/A	-$0.94	N/A	$1.27 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
SMFL Smart for Life	N/A	N/A	N/A	N/A	N/A
TCON TRACON Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TRVN Trevena	N/A	N/A	N/A	N/A	N/A
WINT Windtree Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
SMFL Smart for Life	N/A	N/A	N/A
TCON TRACON Pharmaceuticals	N/A	0.66	0.66
TRVN Trevena	N/A	2.42	2.42
WINT Windtree Therapeutics	N/A	0.43	0.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
SMFL Smart for Life	28.39%
TCON TRACON Pharmaceuticals	11.61%
TRVN Trevena	13.56%
WINT Windtree Therapeutics	29.33%

Insider Ownership

Company	Insider Ownership
SMFL Smart for Life	31.71%
TCON TRACON Pharmaceuticals	5.27%
TRVN Trevena	2.70%
WINT Windtree Therapeutics	0.15%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
SMFL Smart for Life	110	7.09 million	4.84 million	Not Optionable
TCON TRACON Pharmaceuticals	20	3.41 million	3.23 million	No Data
TRVN Trevena	40	959,000	841,000	Optionable
WINT Windtree Therapeutics	30	3.66 million	3.66 million	Not Optionable

TCON, WINT, SMFL, and TRVN Headlines

Recent News About These Companies

Warrington’s Windtree Therapeutics Faces Uncertain Future After NASDAQ Delisting

August 27 at 4:48 PM | msn.com

BNB Treasury Firm Windtree Therapeutics Plunges 77% After Nasdaq Delisting Notice

August 22, 2025 | thecurrencyanalytics.comT

BNB treasury company plunges 77% after Nasdaq delisting notice

August 22, 2025 | cointelegraph.com

BNB hits new all-time high even as treasury company Windtree Therapeutics faces Nasdaq delisting

August 20, 2025 | fxstreet.com

Nasdaq to Delist BNB Treasury Firm Windtree Therapeutics, Stock Crashes 76%

August 20, 2025 | coingape.comC

Windtree Therapeutics Faces Nasdaq Delisting Notice

August 20, 2025 | msn.com

Windtree Therapeutics, Inc. (NASDAQ:WINT) Short Interest Update

August 20, 2025 | americanbankingnews.com

Windtree Therapeutics Delays Q2 2025 Report Filing

August 14, 2025 | tipranks.com

Windtree Announces Istaroxime has been Chosen for a Plenary Session Presentation at the Heart Failure Society of America 2025

August 11, 2025 | globenewswire.com

Windtree Therapeutics Terminates SEISMiC-C Clinical Study

August 11, 2025 | theglobeandmail.com

Windtree Advances Istaroxime Toward Global Phase 3 Following Positive Interim Study Results

August 7, 2025 | msn.com

Windtree Announces Istaroxime Phase 2 Interim Analysis in SCAI Stage C Cardiogenic Shock Patients

August 5, 2025 | taiwannews.com.twT

Windtree Therapeutics Cuts Preferred Stock by Over 99% Ahead of Crypto Strategy Rollout

July 30, 2025 | msn.com

Windtree Therapeutics Announces Large Reduction of Preferred Series C and D Shares Outstanding by Conversion and Redemption

July 29, 2025 | globenewswire.com

Windtree Therapeutics Bets $520M on Binance Coin in Unprecedented Crypto Pivot

July 26, 2025 | thecurrencyanalytics.comT

Windtree Therapeutics Commits Up to $700 Million to Build BNB Treasury Following All-Time High

July 26, 2025 | techstory.inT

Windtree Therapeutics Secures $520 Million in Equity Agreements to Expand BNB Cryptocurrency Holdings

July 26, 2025 | msn.com

Windtree Therapeutics Targets $520 Million in Funding to Secure BNB Reserve

July 25, 2025 | beincrypto.comB

Nasdaq-listed Windtree Therapeutics Commits $520M to BNB in Bold Treasury Pivot

July 25, 2025 | blockonomi.com

Windtree Therapeutics Taps $520M to Build BNB Reserves — Is Pharma Going Crypto?

July 25, 2025 | crypto-news-flash.comC

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCON, WINT, SMFL, and TRVN Company Descriptions

Smart for Life NASDAQ:SMFL

$0.0081 +0.01 (+636.36%)

As of 03:27 PM Eastern

Smart for Life, Inc. acquires, develops, manufactures, operates, markets, and sells nutraceutical and related products in the United States and internationally. It offers natural health and wellness meal replacement products, including nutrition bars, cookies, soups and shakes, vitamins, and supplements under the Smart for Life brand; dietary supplements; and nutritional products, including whey protein isolate powder, tablet supplements for joint health, nitric oxide, post workout blends, Omega-3 supplements, and pre-workout supplements under the Sports Illustrated Nutrition brand for athletes and active lifestyle consumers. The company also provides various nutritional products, including antioxidant rich supplements, plant-based proteins, alkalizing nutrients, and weight management products. It sells its products through online market platforms. The company was formerly known as Bonne Santé Group, Inc. and changed its name to Smart for Life, Inc. in August 2021. Smart for Life, Inc. was founded in 2002 and is based in Boca Raton, Florida.

TRACON Pharmaceuticals NASDAQ:TCON

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. In addition, it is developing bispecific antibodies, which are in preclinical stage. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309 and bispecific antibodies; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.

Trevena NASDAQ:TRVN

$0.25 +0.25 (+20,733.33%)

As of 02:24 PM Eastern

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.

Windtree Therapeutics NASDAQ:WINT

$0.10 0.00 (-0.94%)

As of 03:52 PM Eastern

Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitor for the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time